Bristol Myers Squibbs’ (BMS) investigational drug mavacamten, which reduces cardiac muscle contractility, improved both functional and biomarker outcomes in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM), a form of progressive heart failure.
Source: Drug Industry Daily